Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
Department of Behavioural and Movement Sciences, Section Clinical Psychology, Amsterdam Public Health, van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands.
Qual Life Res. 2021 Jul;30(7):2009-2019. doi: 10.1007/s11136-021-02767-8. Epub 2021 Jan 29.
To measure utilities among cancer patients, a cancer-specific utility instrument called the European Organization for Research and Treatment of Cancer (EORTC) QLU-C10D has been developed based on EORTC quality of life core module (QLQ-C30). This study aimed to provide Dutch utility weights for the QLU-C10D.
A cross-sectional valuation study was performed in 1017 participants representative in age and gender of the Dutch general population. The valuation method was a discrete choice experiment containing 960 choice sets, i.e. pairs of QLU-C10D health states, each health state described in terms of the 10 QLU-C10D domains and the duration of that health state. Each participant considered 16 choice sets, choosing their preferred health state from each pair. Utility scores were derived using generalized estimation equation models. Non-monotonic levels were combined.
Utility decrements were generated for all 10 QLU-C10D domains, with largest decrements for pain (- 0.242), physical functioning (- 0.228), and role functioning (- 0.149). Non-monotonic levels of emotional functioning, pain, fatigue, sleep problems, and appetite loss were combined. No decrement in utility was seen in case of a little or quite a bit impairment in emotional functioning or a little pain. The mean QLU-C10D utility score of the participants was 0.85 (median = 0.91, interquartile range = 0.82 to 0.96).
Dutch utility decrements were generated for the QLU-C10D. These are important for evaluating the cost-utility of new cancer treatments and supportive care interventions. Further insight is warranted into the added value of the QLU-C10D alongside other utility instruments.
为了衡量癌症患者的效用，欧洲癌症研究与治疗组织（EORTC）基于 EORTC 生活质量核心模块（QLQ-C30）开发了一种名为 EORTC QLU-C10D 的癌症特异性效用工具。本研究旨在为 QLU-C10D 提供荷兰效用权重。
在年龄和性别上具有代表性的 1017 名参与者中进行了一项横断面估值研究。该评估方法是一项离散选择实验，包含 960 个选择集，即 QLU-C10D 健康状况的每对，每个健康状况均以 10 个 QLU-C10D 领域和该健康状况的持续时间来描述。每位参与者考虑了 16 个选择集，从每对中选择他们更喜欢的健康状况。使用广义估计方程模型得出效用得分。组合了非单调水平。
为 QLU-C10D 的所有 10 个领域生成了效用递减，其中疼痛（-0.242）、身体功能（-0.228）和角色功能（-0.149）的减幅最大。组合了情感功能、疼痛、疲劳、睡眠问题和食欲减退的非单调水平。在情感功能或轻微疼痛的功能略有或相当程度受损的情况下，没有观察到效用的降低。参与者的平均 QLU-C10D 效用评分得分为 0.85（中位数=0.91，四分位距=0.82 至 0.96）。
为 QLU-C10D 生成了荷兰效用递减。这些对于评估新癌症治疗方法和支持性护理干预措施的成本效用非常重要。需要进一步深入了解 QLU-C10D 与其他效用工具一起的附加价值。
